CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
James Spargo | July 29, 2024 | News story | Research and Development | ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
The opinion is based off positive interim analysis of the phase 3 KEYNOTE-A39 trial, conducted in collaboration with Pfizer and Astellas. KEYTRUDA plus Padcev – an antibody-drug conjugate – showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival.
KEYTRUDA has previously been approved in the EU as a monotherapy for locally advance or metastatic urothelial carcinoma in adults who have not received prior platinum-containing chemotherapy, as well as adults who are not eligible for cisplatin-containing chemotherapy.
Dr Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, commented: “The CHMP’s positive opinion reinforces the landmark results from KEYNOTE-A39. It follows the recent adoption of the European Society for Medical Oncology and European Association of Urology clinical guidelines recommending KEYTRUDA plus enfortumab vedotin as the preferred first-line treatment for patients with advanced or metastatic urothelial carcinoma, regardless of platinum eligibility. We look forward to the European Commission’s decision and are excited to be taking the first steps to provide a potential new first-line standard of care for the treatment of this disease in patients in the EU.”
James Spargo
Related Content
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
